Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors

Trial Profile

Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Cervical cancer; Gastric cancer; Head and neck cancer; Merkel cell carcinoma; Nasopharyngeal cancer; Oesophageal cancer; Penile cancer; Solid tumours; Vulvovaginal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CheckMate358
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
  • Most Recent Events

    • 02 Jun 2017 Updated efficacy and biomarker data will be presented as reported by results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results (n=24) assessing efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results (n=24) assessing efficacy and safety presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top